A Phase 4 interventional study of Triamcinolone 10 Mg/mL Injectable Suspension and Triamcinolone 40 Mg/mL Injectable Suspension in Lumbar Radiculopathy, Sciatica and Back Pain With Radiation, sponsored by University of Miami. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by University of Miami · Phase 4, Interventional, and Treatment
This study aims to evaluate the efficacy of interlaminar steroid injections at treating pain in lumbar radiculopathy at varying doses, to evaluate the efficacy of interlaminar steroid injections at improving quality of life and function in lumbar radiculopathy at varying doses, and to evaluate difference in efficacy between triamcinolone and dexamethasone interlaminar steroid injections at treating pain in lumbar radiculopathy at varying doses, with the overarching hypotheses that there is no difference in reported pain reduction, quality of life, or function among patients receiving low, moderate, or high doses, and no difference in reported pain reduction between triamcinolone and dexamethasone.
483 studies on the registry are indexed under Radiculopathy; 145 are open to participants now.
This study's planned enrollment of 150 is above the median of 60 across 373 interventional studies indexed under Radiculopathy.
Browse Radiculopathy studies →University of Miami is the lead sponsor of 840 studies on the registry; 164 are open to participants now.
Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this arm will receive a single interlaminar lumbar spine steroid injection containing Triamcinolone 10 mg
Drug: Triamcinolone 10 Mg/mL Injectable Suspension
Participants in this arm will receive a single interlaminar lumbar spine steroid injection containing Triamcinolone 40 mg
Drug: Triamcinolone 40 Mg/mL Injectable Suspension
Participants in this arm will receive a single interlaminar lumbar spine steroid injection containing Triamcinolone 80 mg
Drug: Triamcinolone 80 Mg/mL Injectable Suspension
Participants in this arm will receive a single interlaminar lumbar spine steroid injection containing Dexamethasone 2 mg.
Drug: Dexamethasone 2 MG
Participants in this arm will receive a single interlaminar lumbar spine steroid injection containing Dexamethasone 4 mg.
Drug: Dexamethasone 4mg
Participants in this arm will receive a single interlaminar lumbar spine steroid injection containing Dexamethasone 8 mg.
Drug: Dexamethasone 8 MG
Drug page: Triamcinolone
A single 10 mg Triamcinolone interlaminar lumbar epidural steroid injection administered in the lumbar spine.
Also known as: Nasacort® AQ, Kenalog
Drug page: Triamcinolone
A single 40 mg Triamcinolone interlaminar lumbar epidural steroid injection administered in the lumbar spine.
Also known as: Nasacort® AQ, Kenalog
Drug page: Triamcinolone
A single 80 mg Triamcinolone interlaminar lumbar epidural steroid injection administered in the lumbar spine.
Also known as: Nasacort® AQ, Kenalog
A single 2 mg Dexamethasone interlaminar lumbar epidural steroid injection administered in the lumbar spine.
Also known as: Decadron
A single 4 mg Dexamethasone interlaminar lumbar epidural steroid injection administered in the lumbar spine.
Also known as: Decadron
A single 8 mg Dexamethasone interlaminar lumbar epidural steroid injection administered in the lumbar spine.
Also known as: Decadron
Pain Intensity (Numeric Rating Scale 0-10) (NRS)
Pain intensity will be measured using the Numeric Rating Scale (NRS), a validated 0-10 verbal rating scale in which participants rate their pain on a continuum from 0 (pain) to 10 (max pain). Higher scores indicate greater pain severity.
Time frame: Baseline (pre-procedure), 2 weeks post-procedure (±1 week), 6 weeks post-procedure (±2 weeks)]
Physical Function Oswestry Disability Index (ODI)
Physical function will be measured using the Oswestry Disability Index (ODI), a validated Physical Function Scale from 0% to 100%. The ODI consists of multiple sections, each scored from 0 to 5, with higher scores indicating greater functional impairment. The total score is summed and divided by 50 when all sections are completed, or by 45 if the optional section is excluded. Final scores are expressed as a percentage ranging from 0% (minimal disability) to 100% (bed-bound), with higher percentages representing more severe disability.
Time frame: Baseline (pre-procedure), 2 weeks post-procedure (±1 week), 6 weeks post-procedure (±2 weeks)
Quality of Life Short Form 36 (SF-36)
Quality of life will be measured using Quality of Life Measure with domain scores from 0 to 100 with, higher scores indicating better health or fewer limitations in that domain.
Time frame: Baseline (pre-procedure), 2 weeks post-procedure (±1 week), 6 weeks post-procedure (±2 weeks)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for May 2027, 8 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Triamcinolone · Dexamethasone